AAM Announces 2022 Board of Directors | Association for Accessible Medicines

WASHINGTON, DC (February 14, 2022) — The Association for Accessible Medicines (AAM) announced the election of its 2022 Board of Directors and Officers today.

Chirag Patel, President and Co-Chief Executive Officer, Amneal Pharmaceuticals Inc. is the 2022 AAM Chair of the Board. AAM also named Christine Baeder, Senior Vice President, Chief Operating Officer for US Generics, Teva Pharmaceuticals USA, Inc., Vice Chair of the Board and Terry Fullem, President, Jubilant Cadista Pharmaceuticals, Inc., as Treasurer.

Generic drugs saved the U.S. health system $338 billion in 2020, according to AAM's Generic Drug Access & Savings in the U.S. report.

The 2022 AAM Board of Directors includes:

Accord Healthcare, Inc.	Jeff Hampton, President
Ajanta Pharma USA Inc.	Jeff Burd, President
American Regent	Paul Diolosa, President and CEO
Amneal Pharmaceuticals Inc.	Chirag Patel, President and Co-Chief Executive Officer
Amphastar Pharmaceuticals, Inc.	Dan Dischner, Vice President, Corporate Communications
Apotex Corp.	Peter Hardwick, U.S. President and CEO
Aurobindo Pharma USA, Inc.	Paul McMahon, Senior Vice President, Commercial Operations
Cipla USA	Arunesh Verma, Chief Executive Officer
Dr. Reddy's Laboratories, Inc.	Vanessa Brill, Vice President Legal and Compliance, Americas
Fresenius Kabi USA	John Ducker, President and Chief Executive Officer
Glenmark Pharmaceuticals, Inc. USA	Sanjeev Krishan, President, North America
Hikma Pharmaceuticals USA	Brian Hoffmann, President of US Generics
Jubilant Cadista Pharmaceuticals, Inc.	Terry Fullem, President
Lupin Inc.	Alok Sonig, CEO, US Generics and Global Head - Generics R&D & Biosimilars
Mayne Pharma Group Limited	Hem Pandya, Senior Vice President, Head of Generic Products Division
Rhodes Pharmaceuticals L.P.	Vincent Mancinelli II, President
Sagent Pharmaceuticals	Dr. Peter Kaemmerer, Chief Executive Officer
Sandoz Inc., A Novartis Division	Keren Haruvi, President of Sandoz US and Head of North America
Sun Pharmaceutical Industries, Inc. (together with its subsidiary Taro Pharmaceuticals USA, Inc.)	Abhay Gandhi, CEO, North America
Teva Pharmaceuticals USA, Inc.	Christine Baeder, Senior Vice President, Chief Operating Officer for US Generics
Zydus Pharmaceuticals USA, Inc.	Crystal Fisher, Vice President, General Counsel and Compliance Officer

A complete list of 2022 AAM Members can be found here and learn more about each board member here.

MEDIA CONTACT:
Rachel Schwartz
202.249.7147

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.